LVCLF News 0.0670 Living Cell Technologies Limited (LVCLF)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Living Cell Technologies Limited (LVCLF) 0.0670 $LVCLF

'First-in-man' Implant of Regenerative Cell Therapy in Parkinson's Disease
PR Newswire - Thu Sep 19, 9:36PM CDT
Living Cell Technologies Limited (LCT) today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL(R) - a potential treatment for Parkinson's disease.

Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Huntington's Disease - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Huntington's Disease
M2 - Thu Sep 05, 9:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6nbttk/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Huntington's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. Huntington's Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Huntington's Disease. - A review of the Huntington's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Huntington's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 - ACADIA Pharmaceuticals Inc. - Accera, Inc. - Auspex Pharmaceuticals - BrainStorm Cell Therapeutics Inc. - Ceregene, Inc. - CrystalGenomics, Inc. - GW Pharmaceuticals plc - Galenea Corp. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Ipsen S.A. - Isis Pharmaceuticals, Inc. - KineMed, Inc. - Living Cell Technologies Limited - Neuralstem, Inc. - Omeros Corporation - Oryzon - Pfizer Inc. - Prana Biotechnology Limited - Raptor Pharmaceuticals Corp. - SCYNEXIS, Inc. - Siena Biotech S.p.A. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - The Avicena Group, Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - Vybion, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/6n...untingtons About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Huntington's Disease - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:33AM CDT
Research and Markets has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2013" report to their offering. 'Huntington's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Huntington's Disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Huntington's Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indicatio

Hearing Disorders - Pipeline Review, H2 2012
M2 - Thu Jan 17, 3:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/9dlpw7/hearing_disorders) has announced the addition of Global Markets Direct's new report "Hearing Disorders - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Hearing Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hearing Disorders. Hearing Disorders - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Hearing Disorders. - A review of the Hearing Disorders products under development by companies and universities/research institutes based
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 106

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 156

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 79

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 56

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 89

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 221

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 16

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 85

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 88

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 85

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Steers Focus Towards Asia's Streaming Landscape Success

Updated Category News Views 192

Disney Enters the Competitive Asian Streaming Market Walt Disney Co (NYSE: DIS) is strategically positioning itself to dominate in the vibrant Asian streaming market. The company's latest initiative involves a significant investment in original Japanese anime, alongside the expansion of its Korean superhero franchise. With this bold move, Disney aims to establish a strong...

Continue Reading
MSSA and GSMA Unite to Expand Mobile Satellite Services

Updated Category News Views 81

Strategic Alliance of MSSA and GSMA The Mobile Satellite Services Association (MSSA) has announced an exciting new partnership with the GSMA, a leading global organization dedicated to mobile operators and the broader mobile ecosystem. This synergy aims to elevate mobile technology to new heights and transform the landscape of mobile satellite communications. Advancing...

Continue Reading
Celebrating Pioneers: 2025 XCEL Summit for Men Highlights Heroes

Updated Category News Views 259

Honoring Leadership at the 2025 XCEL Summit for Men Black Enterprise is excited to showcase the remarkable individuals receiving the prestigious XCEL Awards at the much-anticipated XCEL Summit for Men. This year's celebration promises to be a hallmark event, scheduled for mid-October at the Hyatt Regency Grand Cypress in Orlando. Attendees can expect a magnificent...

Continue Reading
Innovative Trial Launches to Combat Pediatric Leukemia Worldwide

Updated Category News Views 259

Revolutionizing Pediatric Leukemia Treatment The Leukemia & Lymphoma Society (LLS) has embarked on an extraordinary journey with the launch of the PedAL (Pediatric Acute Leukemia) Master Clinical Trial, a trailblazing effort that marks the world's first-ever global trial focused on menin inhibitors for treating pediatric leukemia. This initiative is part of LLS's broader...

Continue Reading
Aflac Partners with Workday to Enhance Employee Benefits Experience

Updated Category News Views 196

Aflac's Collaboration with Workday for Enhanced Wellness Solutions Aflac, a prominent provider of supplemental insurance in the U.S., has entered into a partnership with Workday Wellness aimed at revolutionizing employee benefit offerings. This strategic relationship empowers employers to provide a more personalized experience for their workforce, ultimately aimed at...

Continue Reading